Rapidscan Pharma Solutions

LONDON, January 26, 2011 - Today Rapidscan Pharma Solutions (RPS) EU Ltd announced it has received marketing authorization for Rapiscan(R) (regadenoson) - a selective coronary vasodilator for use as a pharmacological stress agent in the diagnosis of coronary artery disease (CAD) - the single most common cause of death and disability in Europe[1].